← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant use after resection and platinum-based chemotherapy in stage IB with a T2a tumor at least 4 cm, stage II, or stage IIIA NSCLC.

LAMPGEN ANALYSIS

Why it matters

The indication added postoperative immunotherapy following platinum treatment.

What research teams should watch

Document pathologic staging, tumor size, resection and completed chemotherapy to distinguish this indication from perioperative use.

PRIMARY RECORDS

Sources